Author: Business Wire

ソウル半導体の自然光LED、臨床試験で、目の疲労や睡眠の質に効果

韓国安山市–(BUSINESS WIRE)–世界的なLED (発光ダイオード)専業メーカーのSeoul Semiconductor Co., Ltd. (本社:韓国安山市、代表理事:李貞勲、以下「ソウル半導体」)は、自社の先端技術で開発した自然光LEDの”SunLike”が睡眠の質の向上と目の健康に有益な、ヒューマンセントリック照明に最適化されたLED製品であるという研究結果が出たと発表した。

Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Randall Brown as Director, Payer Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Brown will support the ongoing development and execution of strate

Vivior a clôturé un tour de financement avec des investisseurs privés originaires d’Europe et des États-Unis

ZURICH–(BUSINESS WIRE)–La cataracte, ou opacification du cristallin, affecte plus de 50 millions de personnes chaque année à travers le monde. Le traitement standard consiste à implanter une lentille intraoculaire (LIO) artificielle. Les chirurgiens ophtalmologistes s’appuient actuellement sur des entretiens subjectifs avec les patients pour choisir la puissance et le type de lentille intraoculaire artificielle, ce qui peut conduire à des résultats décevants pour les patients si ce choix n’es

Vivior hat Finanzierungsrunde mit privaten Investoren aus Europa und den USA abgeschlossen

ZÜRICH–(BUSINESS WIRE)–Weltweit sind mehr als 50 Millionen Menschen pro Jahr vom grauen Star, der Trübung der Linse des Auges, betroffen. Die Implantation einer künstlichen Intraokularlinse (IOL) ist dabei die übliche Behandlungsmethode. Augenchirurgen wählen die Brechkraft und den Typ der IOL aufgrund von Gesprächen mit den Patienten, was infolge der subjektiven Informationen zu unbefriedigenden Ergebnissen führen kann, wenn die Wahl der Linse nicht korrekt oder passend ist. Ein neuartiges t

Resumen: Vivior cierra ronda de financiación con inversores privados de Europa y EE. UU.

ZURICH–(BUSINESS WIRE)–Las cataratas, la opacidad de la lente del ojo, afectan a más de 50 millones personas cada año en todo el mundo. El tratamiento habitual consiste en implantar una lente intraocular artificial (IOL en sus siglas en inglés). En la actualidad, los cirujanos oftálmicos confían en entrevistas subjetivas a los pacientes al seleccionar la potencia y el tipo de IOL, lo que puede derivar en resultados insatisfactorios para los pacientes si esta opción no es exacta o adecuada. Un

Riassunto: Vivior conclude un round di finanziamento con investitori privati di Europa e Stati Uniti

ZURIGO–(BUSINESS WIRE)–La cataratta, l’annebbiamento del cristallino, è una patologia oculare che colpisce ogni anno oltre 50 milioni di persone nel mondo. Il trattamento standard prevede l’impianto di una lente intraoculare artificiale (IOL). Attualmente i chirurghi oftalmici selezionano il tipo e la gradazione della lente IOL in base a interviste soggettive dei pazienti ma, se la scelta non è precisa o adatta, i risultati per i pazienti possono essere insoddisfacenti. Un nuovo sistema indos

Oyster Point Pharma Announces Positive Results from Phase 2 Clinical Trial of the Company’s Investigational Treatment for Dry Eye Disease

PRINCETON, N.J.–(BUSINESS WIRE)–#AECOS–Oyster Point Pharma, Inc., today announced results from the PEARL study, a Phase 2b clinical trial evaluating the company’s novel therapy for the treatment of Dry Eye Disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a vehicle control. Topline data from the study will be presented at the American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Vall

Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018

PALO ALTO, Calif.–(BUSINESS WIRE)–Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, is pleased to announce the latest liquidity events for eight (8) of its portfolio companies: DocuSign, Inc., Tricida, Inc. and BridgeBio Inc./Eidos Therapeutics, Inc., which recently completed their initial public offerings (“IPO”); and Inotek Pharmaceuticals Corporati

NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth

EMERYVILLE, Calif.–(BUSINESS WIRE)–$NBY #Avenova–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of who